Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Epivir
Epivir 150 mg film-coated tablets Epivir 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-085844 · Präparat HOS-083204
Coadministration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose of lamivudine
oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure
(AUC) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. When possible, avoid chronic
coadministration of Epivir with medicinal products containing sorbitol or other osmotic acting poly-
alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent
monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage 11d4c71ff0534304a2835be74b7f4affa51a0ac28c73319f4a74053c35ba3167 · Zeichen 2436–3013 im Abschnitt
Wechselwirkungen · Epivir
Epivir 10 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 22
HOS-085877 · Präparat HOS-083204
Coadministration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose of lamivudine
oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure
(AUC) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. When possible, avoid chronic
coadministration of Epivir with medicinal products containing sorbitol or other osmotic acting poly-
alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent
monitoring of HIV-1 viral load when chronic coadministration cannot be avoided (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T14:36:00Z · SHA-256 dda482a8b09324ebc742f0589dd9c287ef99dfaee8f30a2889bc848f23ef2100 · Passage f7c0fa53835fa163ad7f651dc45814ad5030a10fca0244b9df26320c87a0ff15 · Zeichen 2439–3034 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-088518 · Präparat HOS-083663
Methadone dosage adjustment
unlikely in majority of
patients; occasionally
methadone re-titration may be
required.
URICOSURIC
Probenecid/Lamivudine Interaction not studied. As only limited data are
Probenecid/Zidovudine Zidovudine AUC 106% available the clinical
(500 mg four times significance is not known.
daily/2mg/kg thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
MISCELLANEOUS
Sorbitol solution (3.2g , 10.2 g, Single dose lamivudine oral When possible, avoid chronic
13.4 g)/ Lamivudine solution 300 mg coadministration of Combivir
with medicinal products
Lamivudine:
containing sorbitol or other
AUC 14%; 32%; 36% osmotic acting poly-alcohols
or monosaccharide alcohols
Cmax 28%; 52%, 55%. (e.g. xylitol, mannitol, lactitol,
maltitol). Consider more
frequent monitoring of HIV-1
viral load when chronic
coadministration cannot be
avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) methadone (HOS-086198) xylitol (HOS-085846) mannitol (HOS-085847) probenecid (HOS-085208) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage c60e9a85277b6d563917784e4dc019a6b2a7eb8117d4abdfd711dea58f60eabc · Zeichen 8504–10729 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 100 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 7
HOS-089945 · Präparat HOS-083949
Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (adult HIV
daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14 %, 32 %, and 36 %
in lamivudine exposure (AUC) and 28 %, 52 %, and 55 % in the Cmax of lamivudine in adults. When
possible, avoid chronic co-administration of Zeffix with medicinal products containing sorbitol or
other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol,
maltitol). Consider more frequent monitoring of HBV viral load when chronic co-administration
cannot be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage c90d925649dbf281e1d4671b10f760554b3a126786ddf839b43874cb3c156eb2 · Zeichen 2517–3123 im Abschnitt
Wechselwirkungen · Zeffix
Zeffix 5 mg/ml oral solution. · Abschnitt 4.5 · PDF-Seite 22
HOS-089971 · Präparat HOS-083949
Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (adult HIV
daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14 %, 32 %, and 36 %
in lamivudine exposure (AUC) and 28 %, 52 %, and 55 % in the Cmax of lamivudine in adults. When
possible, avoid chronic co-administration of Zeffix with medicinal products containing sorbitol or
other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol,
maltitol). Consider more frequent monitoring of HBV viral load when chronic co-administration
cannot be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T15:02:00Z · SHA-256 68d15b158db220a54d54ada9418a4232cc18c7b756744628ac3b16f2fb588c40 · Passage c90d925649dbf281e1d4671b10f760554b3a126786ddf839b43874cb3c156eb2 · Zeichen 2516–3122 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-108571 · Präparat HOS-093047
11
Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine oral When possible, avoid chronic
13.4 g)/ Lamivudine solution 300 mg coadministration of Trizivir
with medicinal products
Lamivudine:
containing sorbitol or other
AUC 14%; 32%; 36% osmotic acting poly-alcohols
or monosaccharide alcohols
Cmax 28%; 52%, 55%. (e.g. xylitol, mannitol,
lactitol, maltitol). Consider
more frequent monitoring of
HIV-1 viral load when
chronic coadministration
cannot be avoided.
Riociguat/Abacavir Riociguat Riociguat dose may need to
be reduced. Consult the
In vitro, abacavir inhibits
riociguat prescribing
CYP1A1. Concomitant
information for dosing
administration of a single dose
recommendations.
of riociguat (0.5 mg) to HIV
patients receiving the
combination of
abacavir/dolutegravir/lamivudine
(600 mg/50 mg/300 mg once
daily) led to an approximately
three-fold higher riociguat
AUC(0-∞) when compared to
historical riociguat AUC(0-∞)
reported in healthy subjects.
Abbreviations: = Increase; =decrease; = no significant change; AUC=area under the
concentration versus time curve; Cmax=maximum observed concentration; CL/F=apparent oral
clearance
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) riociguat (HOS-086293) dolutegravir (HOS-089992) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage c4b1bb4a035cf3db319c881110ad4d95c1fe80a0464010149efaf1c0e709d897 · Zeichen 13071–15827 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-113484 · Präparat HOS-093937
9
Drugs by Therapeutic Area Interaction Recommendation concerning
Geometric mean change (%) co-administration
(Possible mechanism)
MISCELLANEOUS
Ethanol/Abacavir Abacavir: AUC 41% No dosage adjustment
(0.7 g/kg single dose/600 mg Ethanol: AUC necessary.
single dose)
(Inhibition of alcohol
dehydrogenase)
Ethanol/Lamivudine Interaction not studied.
Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine oral When possible, avoid chronic
13.4 g)/ Lamivudine solution 300 mg coadministration of Kivexa
with medicinal products
Lamivudine:
containing sorbitol or other
AUC 14%; 32%; 36% osmotic acting poly-alcohols
or monosaccharide alcohols
Cmax 28%; 52%, 55%.
(e.g. xylitol, mannitol, lactitol,
maltitol). Consider more
frequent monitoring of HIV-1
viral load when chronic
coadministration cannot be
avoided.
Riociguat/Abacavir Riociguat Riociguat dose may need to be
reduced. Consult the riociguat
In vitro, abacavir inhibits
prescribing information for
CYP1A1. Concomitant
dosing recommendations.
administration of a single dose
of riociguat (0.5 mg) to HIV
patients receiving the
combination of
abacavir/dolutegravir/lamivudine
(600 mg/50 mg/300 mg once
daily) led to an approximately
three-fold higher riociguat
AUC(0-∞) when compared to
historical riociguat AUC(0-∞)
reported in healthy subjects.
Abbreviations: = Increase; = decrease; = no significant change; AUC = area under the concentration versus time curve;
Cmax = maximum observed concentration; CL/F = apparent oral clearance
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) riociguat (HOS-086293) dolutegravir (HOS-089992) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) ethanol (HOS-089988) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage c09fdc59a015e3b2b3a286b35a04e7296fbae59f17fc94feb678df0b8e6dd0d8 · Zeichen 8444–12119 im Abschnitt
Wechselwirkungen · Lamivudine Teva Pharma B.V.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine Teva Pharma B.V. 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211914 · Präparat HOS-154784
Coadministration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose of lamivudine
oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure
(AUC∞) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. When possible, avoid chronic
coadministration of Lamivudine Teva Pharma B.V. with medicinal products containing sorbitol or
other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol,
maltitol). Consider more frequent monitoring of HIV-1 viral load when chronic coadministration
cannot be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-21T15:48:00Z · SHA-256 20f7e52b86e41eb238a7c02628d41f826d204c97eddc200b9de9d5dfd73ec34c · Passage 907dc685998f6cce489560116bab354a9de64865cc83d1152b1044cef9f5ed0f · Zeichen 2365–2962 im Abschnitt
Wechselwirkungen · Lamivudine Teva
Lamivudine Teva 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211998 · Präparat HOS-154800
Sorbitol
Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV
daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in
lamivudine exposure (AUC∞) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. When
possible, avoid chronic co-administration of Lamivudine Teva with medicinal products containing
sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol,
lactitol, maltitol). Consider more frequent monitoring of HBV viral load when chronic co-
administration cannot be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-07T02:00:00Z · SHA-256 7ebfd130ef9d9ca18166e2a55526570d39c018726558f43f8bad673f541d0883 · Passage 68fac57b5f60b7f847200e3a57f72b2823f8352782ab897cc3e4ccec57469aa5 · Zeichen 2465–3084 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-129272 · Präparat HOS-096703
Sorbitol
Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine When possible, avoid chronic
13.4 g)/Lamivudine oral solution 300 mg coadministration of Triumeq with
medicinal products containing sorbitol
Lamivudine:
or other osmotic acting poly-alcohols or
AUC ↓ 14%; 32%; 36% monosaccharide alcohols (eg: xylitol,
mannitol, lactitol, maltitol). Consider
Cmax ↓ 28%; 52%, 55%.
more frequent monitoring of HIV-1 viral
load when chronic coadministration
cannot be avoided.
Potassium channel blockers
Fampridine (also known as Fampridine ↑ Co-administration of dolutegravir has
dalfampridine)/Dolutegravir the potential to cause seizures due to
increased fampridine plasma
concentration via inhibition of OCT2
transporter; co-administration has not
been studied. Fampridine co-
administration with Triumeq is
contraindicated (see section 4.3).
Antacids and supplements
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) xylitol (HOS-085846) dalfampridine (HOS-124191) mannitol (HOS-085847) lactitol (HOS-085848) potassium (HOS-086929) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 1e69963a06cb46bc20e212ed907227e0d44e3697e23d1ae35270ea2927f9d4a5 · Zeichen 22679–24574 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 50
HOS-129363 · Präparat HOS-096703
Sorbitol
Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine When possible, avoid chronic
13.4 g)/Lamivudine oral solution 300 mg coadministration of Triumeq with
medicinal products containing sorbitol
Lamivudine:
or other osmotic acting poly-alcohols or
AUC ↓ 14%; 32%; 36% monosaccharide alcohols (eg: xylitol,
mannitol, lactitol, maltitol). Consider
Cmax ↓ 28%; 52%, 55%.
more frequent monitoring of HIV-1 viral
load when chronic coadministration
cannot be avoided.
Potassium channel blockers
Fampridine (also known as Fampridine ↑ Co-administration of dolutegravir has
dalfampridine)/Dolutegravir the potential to cause seizures due to
increased fampridine plasma
concentration via inhibition of OCT2
transporter; co-administration has not
been studied. Fampridine co-
administration with Triumeq is
contraindicated (see section 4.3).
Antacids and supplements
Magnesium/ Dolutegravir ↓ Magnesium/ aluminium-containing
aluminium-containing AUC ↓ 74% antacids should be taken well separated
antacids/Dolutegravir Cmax ↓ 72% in time from the administration of
Triumeq (minimum 2 hours after or 6
(Complex binding to hours before the intake of Triumeq).
polyvalent ions)
Calcium Dolutegravir ↓ - When taken with food, Triumeq and
supplements/Dolutegravir AUC ↓ 39% supplements or multivitamins containing
Cmax ↓ 37% calcium, iron or magnesium can be taken
C24 ↓ 39% at the same time.
(Complex binding to - If Triumeq is taken in a fasted state,
polyvalent ions) such supplements should be taken a
Iron supplements/Dolutegravir Dolutegravir ↓ minimum 2 hours after or 6 hours before
AUC ↓ 54% the intake of Triumeq.
Cmax ↓ 57%
C24 ↓ 56%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) calcium (HOS-085615) iron (HOS-085656) xylitol (HOS-085846) dalfampridine (HOS-124191) mannitol (HOS-085847) lactitol (HOS-085848) potassium (HOS-086929) magnesium (HOS-085165) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage e1b3a9b322dc8105f415a52dcb6e350ae5cd5eb4c2cfe44e909aca42e727f58f · Zeichen 19030–22339 im Abschnitt
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-141212 · Präparat HOS-098610
13
Recommendation concerning
Medicinal product by Effects on medicinal product levels co-administration with
therapeutic area geometric mean ratio (90 % CI)* doravirine/lamivudine/tenofovir
disoproxil
Immunosuppressants
Interaction not studied with
doravirine or
doravirine/lamivudine/tenofovir
Monitor blood concentrations of
tacrolimus disoproxil.
tacrolimus and sirolimus as the
sirolimus
dose of these agents may need to
Expected:
be adjusted.
doravirine
↓ tacrolimus, sirolimus
(Induction of CYP3A)
Kinase inhibitors
Interaction not studied with Co-administration should be
doravirine or avoided. If co-administration
doravirine/lamivudine/tenofovir cannot be avoided, a 100 mg dose
disoproxil. of doravirine should be taken
dabrafenib daily, approximately 12 h after the
Expected: dose of
↓ doravirine doravirine/lamivudine/tenofovir
(Induction of CYP3A) disoproxil.
Miscellaneous
Single dose lamivudine oral solution When possible, avoid chronic co-
300 mg administration of
doravirine/lamivudine/tenofovir
lamivudine disoproxil with medicinal
AUC 14 %; 32 %; 35 % products containing sorbitol or
sorbitol solution (3.2 g,
Cmax 28 %; 52 %; 55 % other osmotic acting poly-alcohols
10.2 g, 13.4 g)/lamivudine
(e.g., xylitol, mannitol, lactitol,
maltitol). Consider more frequent
monitoring of HIV-1 viral load
when chronic co-administration
cannot be avoided.
Opioid analgesics
doravirine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) maltitol (HOS-085849) dabrafenib (HOS-109452) xylitol (HOS-085846) mannitol (HOS-085847) lactitol (HOS-085848) tacrolimus (HOS-085202) sirolimus (HOS-085172) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage 751eaf990e8670670ff84bf67ddbc2d6bcc8619ddb393e820239d314937e39b5 · Zeichen 26023–29336 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-142841 · Präparat HOS-098886
10
Cytotoxics
Cladribine/Lamivudine Interaction not studied. Concomitant use of Dovato with
cladribine is not recommended (see
In vitro lamivudine section 4.4).
inhibits the intracellular
phosphorylation of
cladribine leading to a
potential risk of cladribine
loss of efficacy in case of
combination in the
clinical setting. Some
clinical findings also
support a possible
interaction between
lamivudine and
cladribine.
Miscellaneous
Sorbitol
Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine When possible, avoid chronic
13.4 g)/Lamivudine oral solution 300 mg. coadministration of Dovato with
medicinal products containing sorbitol
Lamivudine:
or other osmotic acting poly-alcohols or
AUC 14%; 32%; 36% monosaccharide alcohols (eg: xylitol,
mannitol, lactitol, maltitol). Consider
Cmax 28%; 52%, 55%.
more frequent monitoring of HIV-1 viral
load when chronic coadministration
cannot be avoided.
Potassium channel blockers
Fampridine (also known as Fampridine Co-administration of dolutegravir has
dalfampridine)/Dolutegravir the potential to cause seizures due to
increased fampridine plasma
concentration via inhibition of OCT2
transporter; co-administration has not
been studied. Fampridine co-
administration with Dovato is
contraindicated (see section 4.3).
Antacids and supplements
Magnesium/ Dolutegravir Magnesium/ aluminium-containing
aluminium-containing AUC 74% antacids should be taken well separated
antacids/Dolutegravir Cmax 72% in time from the administration of
Dovato (minimum 2 hours after or
(Complex binding to 6 hours before).
polyvalent ions)
Calcium Dolutegravir - When taken with food, Dovato and
supplements/Dolutegravir AUC 39% supplements or multivitamins containing
(fasted intake) Cmax 37% calcium, iron or magnesium can be taken
C24 39% at the same time.
(Complex binding to - If Dovato is taken in a fasted state,
polyvalent ions) such supplements should be taken a
Iron supplements/Dolutegravir Dolutegravir minimum 2 hours after or 6 hours before
(fasted intake) AUC 54% the intake of Dovato.
Cmax 57%
C24 56% The stated reductions in dolutegravir
(Complex binding to exposure were observed with the intake
polyvalent ions) of dolutegravir and these supplements
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) calcium (HOS-085615) iron (HOS-085656) xylitol (HOS-085846) dalfampridine (HOS-124191) mannitol (HOS-085847) lactitol (HOS-085848) potassium (HOS-086929) magnesium (HOS-085165) sorbitol (HOS-085845) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 2518b802c4caa948477bdcec36197fbfdc295ad3c0b1c09f9b968f8a51fd6feb · Zeichen 18693–23302 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.